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Background: As HIV infection turned into a chronic treatable disease, now ranking as one of 
the most costly in medicine, long-term sustainability of highly active antiretroviral treatment 
(HAART) expenses became a major issue, especially in countries with universal access to care. 
Identification of determinants of higher HAART costs may therefore help in controlling costs 
of care, while keeping high levels of retention in care and viral suppression.
Methods: With this aim, we enrolled a large multicentric sample of consecutive unselected 
human immunodeficiency virus (HIV) patients followed at five sites of care in Italy, and evalu-
ated annual individual HAART costs in relation to a number of sociodemographic, clinical, 
and laboratory variables.
Results: We enrolled 2,044 patients, including 1,902 on HAART. Mean HAART costs were 
€9,377±€3,501 (range 782–29,852) per year, with remarkable site-based differences, possibly 
related to the different composition of local assisted populations. Percentages of patients on 
viral suppression were homogeneously high across all study sites. The factors identified by 
cross-validation were line of HAART, diagnosis of acquired immune deficiency syndrome, 
current CD4 T-cell count, and detectable HIV viremia .50 copies/mL. In the final multivariable 
model, HAART costs were independently directly associated with more advanced HAART line 
(P,0.001) and inversely correlated with current CD4 T-cell count (P=0.024). Site of care held 
independent prediction of higher costs, with marked control of expenses at sites 2 (P=0.001) 
and 5 (P,0.001).
Conclusion: Higher costs of HAART were strongly associated with previous treatment 
failures, detectable HIV viremia, and lower CD4 T-cell count at the time of evaluation, with 
no correlation at all with sex, age, hepatitis C virus coinfection, and nadir CD4 T-cell counts. 
Newer drugs, which are typically those associated with high prices, at the time of the analysis 
were still prevalently prescribed to rescue and maintain viral suppression in patients with more 
complex treatment history. Further analyses of the contribution of the single drug/regimen to 
the estimated cost are warranted.
Keywords: highly active antiretroviral treatment, human immunodeficiency virus, costs, treat-
ment failures, viremia, current CD4 count
Introduction
With the advent of combined highly active antiretroviral therapy (HAART), human 
immunodeficiency virus (HIV) turned into a chronic treatable disease, compatible 
with near normal lifespan expectancy.1–3 As a consequence of increased survival of 
both early and advanced HIV infections, expenditure for HIV care is now ranking as 
one of the most costly chronic diseases.1,4 Indeed, even though costs for HIV hospital 
admissions have somewhat decreased,5,6 especially in patients with early diagnosis, 
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total costs for HIV care are getting higher and higher in line 
with the following trends: increasing costs of newer anti-
retrovirals, larger numbers of patients on chronic therapy, 
guidelines suggesting early prescription of HAART, and 
early access to treatment as prevention.5,7–10
The majority of industrialized countries strive to guar-
antee long-term sustainability for lifelong antiretroviral 
treatment of HIV patients. Universal access to care seems 
to be indeed helpful for patients’ retention in care in 
some European countries like Italy and Denmark, where 
physicians may prescribe antiretrovirals in the absence of 
immediate control of expenses and current results regard-
ing retention in care and HAART efficacy are suggestive 
of adequacy.11–14
As the costs of HAART regimens are relatively easy 
to determine and analyze, in the present study we set up a 
research protocol to retrospectively assess the issue of which 
factors are associated with the use of more costly HAART 
regimens in clinical practice. We wondered whether costs 
might be presently associated with sociodemographic and 
clinical features of our patients, or rather with other condi-
tioning factors.
Materials and methods
A retrospective unselected sample of consecutive HIV outpa-
tients aged .18 years and followed at five sites of care well 
spread throughout Italy was collected for a cross-sectional 
evaluation of cost determinants in 2012. We considered 
sociodemographic characteristics (age, sex), risk factors for 
HIV infection (heterosexual, homosexual, intravenous drug 
use, blood transfusion), current HIV viral load (copies/mL, 
Roche Amplicor®), current (at the time of cost evaluation) and 
nadir CD4 T-cell counts (cells/mm3), time from HIV diagnosis, 
acquired immune deficiency syndrome (AIDS)-defining events 
(ever reported during clinical history), current HAART line, 
and hepatitis C virus (HCV) coinfection, as already defined 
elsewhere.15 Years from HIV diagnosis were calculated as the 
difference between 2012 and the year when HIV infection was 
first diagnosed. Line of HAART was defined on the basis of 
the number of treatment changes due to virological failure; 
simplification or switch for side effects were not considered as 
a change of HAART line. Annual costs of individual HAART 
regimens were calculated using pharmacy data retrieved at 
each distribution site as of December 2012.
statistical analysis
The outcome was the cost of the regimen currently used 
by the patients. Costs were modeled in the original raw 
scale as the distribution was approximately normal and the 
log  transformation only marginally reduced the skewness. 
 Univariable analyses for determinants of higher HAART 
costs were set up for all the investigated variables. The basic 
set of covariates were: line of HAART, age, AIDS event, cur-
rent CD4 T-cell count, time since HIV diagnosis, coinfection 
with HCV, nadir CD4 T-cell count, risk for HIV infection, 
sex, and detectable HIV RNA .20 copies/mL. Initially, 
the potential independent predictors of HAART costs were 
evaluated using a multivariable regression model, including 
all covariates that were significantly associated with costs 
in the univariable analyses. Statistical significance was 
defined as a two-sided P-value ,0.05 for all analyses, and 
multiple regression models were fit using Stata version 10.1 
(Stata Corporation, College Station, TX, USA). In addition 
to this approach, three different criteria for the selection of 
covariates in the model were used, similar to what was done 
by Cozzi-Lepri et al:16 best subset least squared estimations, 
least absolute shrinkage and selection operator,17 and a mixed 
approach using both least angle regression and least absolute 
shrinkage and selection operator.18 In all these methods, 
model sequencing is determined by the original algorithm, 
while the coefficients of the parameters at each step are 
determined using ordinary least squares. Both least absolute 
shrinkage and selection operator and least angle regression 
are shrinkage methods for linear regression that minimize the 
sum of squared errors though with a bound on the sum of the 
absolute values of the coefficients given by a  parameter K. 
This parameter K was chosen to minimize the average squared 
error based on a 10-fold cross-validation. Briefly, to perform a 
10-fold cross-validation means to randomly divide the dataset 
into ten portions of the same size. The method then fits the 
model for a range of values of K to 9/10th of the data and 
computes the prediction error on the remaining 1/10th. This is 
done, in turn, for each of the 1/10 portions, and eventually the 
mean of these ten obtained estimates of the prediction error 
is calculated. Using this approach, we obtained an estimated 
prediction of the 10-fold cross-validation error (CV PRESS) 
curve as a function of the model evolution steps. This was 
used to establish at which step to stop the inclusion of the 
covariates. Specifically, the “one-standard-error” rule was 
used to select the final model: the model with the smaller 
number of included covariates providing a CV PRESS within 
one standard error of its minimum value. Cross-validation 
was applied to our database (by randomly splitting 50% as 
training, 25% as validation, and 25% as test set) to select K 
for all estimation procedures. Of note, the training set is used 
to determine the coefficients but not to decide when to stop. 
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The results of the cross-validation in terms of selection of 
the most important predictors were similar when using the 
costs in the raw or the log scale. All these additional analyses 
were performed using the procedure GLMSELECT in SAS 
version 9.3 (SAS Institute, Cary, NC, USA).
Results
We included 2,044 patients, 69.0% of whom were male. The 
mean patient age was 46.9±10.0 years, and 33.4% of patients 
were coinfected with HCV. The risk for HIV infection was 
heterosexual contact (881 patients, 43.7%), homosexual con-
tact (519 patients, 25.7%), intravenous drug use (591 patients, 
29.3%), and blood transfusion (25 patients, 1.2%). Mean time 
since HIV diagnosis was 13.6±7.9 years. Mean nadir CD4 
T-cell counts were 230.0±169.3 cells/mm3, mean current CD4 
T-cell counts were 579.0±299.0 cells/mm3. An AIDS diagnosis 
was recorded for 30.8% of patients. Significant differences 
in demographic and clinical features were observed between 
patients cared for at different sites, as shown in Table 1.
There were 1,902 (93.0%) evaluable patients on HAART. 
Among them, viremic ($20 copies/mL) patients were 
31.2% (635 patients); only 19.0% (387 patients), however, 
had HIV RNA values .50 copies/mL. Median HAART 
line was 3.47±2.08. Mean individual HAART costs were 
€9,377±€3,501 (range 782–29,852) per year. Costs were 
Table 1 Demographic and viro-immunological characteristics of the sample overall and by site
Site (patients) Overall 
(n=2,044)
Site 1 
(n=241)
Site 2 
(n=464)
Site 3 
(n=690)
Site 4 
(n=285)
Site 5 
(n=364)
P-value*
Male sex, n (%) 1,410 (70.0) 178 (73.9) 300 (64.6) 461 (66.8) 221 (77.5) 114 (68.7) 2vs1; 3vs1; 4vs2; 4vs3; 5vs4
Mean (sD) age, years 46.9 (10.1) 45.5 (9.1) 45.2 (8.9) 49.0 (9.2) 46.6 (11.2) 47.7 (11.4) 3vs1; 3vs2; 4vs3; 5vs3
iVDU, n (%) 591 (29.3) 60 (24.9) 105 (22.6) 289 (42.6) 51 (17.9) 86 (24.8) 3vs1; 3vs2; 4vs3; 5vs3; 5vs4
aiDs, n (%) 615 (30.8) 96 (39.8) 151 (32.5) 220 (31.9) 51 (17.9) 97 (30.4) 3vs1; 4vs1; 4vs2; 4vs3; 5vs1
CD4 T-cell nadir,  
mean (sD)
232 (171) 237 (186) 255 (187) 187 (114) 325 (230) 211 (135) 2vs1; 3vs2; 4vs1; 4vs2; 
4vs3; 5vs2; 5vs4
Current CD4 T-cell  
count, mean (sD)
579 (299) 511 (280) 592 (305) 552 (287) 681 (340) 578 (270) 4vs1; 4vs2; 4vs3; 5vs4
naïve to haaRT,  
n (%)
142 (7.0) 20 (8.3) 60 (12.9) 22 (3.2) 40 (14.0) 0 (0) 3vs1; 3vs2; 4vs1; 4vs3; 
5vs1; 5vs2; 5vs3
hCV coinfection, n (%) 682 (33.4) 68 (28.2) 129 (27.8) 317 (45.9) 77 (27.3) 91 (25.0) 3vs1; 3vs2; 4vs3; 5vs3
Mean (sD) time from  
hiV infection, years
13.6 (7.9) 13.2 (7.4) 13.9 (8.4) 15.5 (7.7) 8.2 (5.2) 12.3 (7.6) 3vs1; 3vs2; 4vs1; 4vs2; 
4vs3; 5vs2; 5vs3; 5vs4
Detectable viremia  
.20 cp/ml, n (%)
635 (31.2) 68 (28.3) 112 (24.2) 306 (44.4) 85 (30.1) 64 (17.6) 3vs1; 3vs2; 4vs3; 5vs1; 
5vs3; 5vs4
Detectable viremia  
.50 cp/ml, n (%)
387 (19.0) 47 (19.6) 103 (22.3) 114 (16.6) 59 (21.0) 64 (17.6) ns
Mean (sD) haaRT  
costs, €
9,377 (3,501) 9,168 (3,252) 8,881 (3,600) 10,042 (3,322) 9,515 (2,876) 8,728 (4,028) 3vs1; 3vs2; 5vs3; 5vs4
Notes: CD4 T-cell counts are expressed as cell/mm3. haaRT costs are calculated as annual costs of haaRT per single patient. site 1, Pescara; site 2, ancona; site 3, 
genoa; site 4, Pistoia; site 5, Catania. *One-way analysis of variance with sidak correction for continuous variables, chi-squared test for categorical variables. head-to-head 
comparisons among groups were made and are reported as follows: ie, 3vs2 means that the comparison between group 3 and group 2 was significant (P,0.05).
Abbreviations: AIDS, acquired immune deficiency syndrome; cp, copies; HAART, highly active antiretroviral therapy; HCV, hepatitis C virus; HIV, human immunodeficiency 
virus; IVDU, intravenous drug use; NS, any difference across groups was significant; SD, standard deviation.
significantly different at the five sites of care, as indicated 
in Table 1.
Univariable analyses for higher HAART costs were set 
up for all the investigated variables. All of them were associ-
ated with higher HAART costs with the exception of sex, as 
shown in Table 2.
When we used the best subset selector least squared esti-
mates of the coefficients and 10-fold cross-variation to identify 
our best multivariable predictive model, starting from the full 
set of measured variables, the following factors were selected: 
line of HAART (parameter estimate = +€557 per additional 
regimen), AIDS diagnosis (estimate = +€351 compared with 
asymptomatic), current CD4 T-cell count (estimate = -€629 
for those having .200 and ,500 cells/mm3 current CD4 count 
comparing with those having #200 cells/mm3, and -€1,135 
for those having .500 cells/mm3 current CD4 count) and HIV 
viral load .50 copies/mL (estimate = +€405 compared with 
viral load #50 copies/mL). Figure 1 shows the relative impor-
tance of these factors at each step of the selection process, and 
provides information as to when effects entered the model (the 
estimates above are derived directly from the standardized 
coefficients at final step number 4; a negative estimate means 
a negative impact on costs). Thus, for example, the line of 
HAART is the first factor to be entered in the model with an 
estimated coefficient close to 0.4 (step 1). In the following three 
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Table 2 individual annual haaRT costs according to selected 
variables
Mean (SD) cost, € P-value*
sex 0.6
 Male 9,400 (3,585)
 Female 9,324 (3,309)
haaRT line ,0.001
 First 8,016 (2,311)
 second 8,185 (2,000)
 Third 8,915 (2,656)
 Fourth 9,545 (2,801)
 Fifth 10,065 (3,530)
 sixth 10,733 (4,311)
 seventh 11,415 (5,491)
 Eighth 13,077 (5,909)
iVDU 0.0001
 no 9,189 (3,434)
 Yes 9,860 (3,647)
aiDs ,0.001
 no 9,090 (3,102)
 Yes 10,015 (4,043)
hCV coinfection 0.0007
 negative 9,187 (3,476)
 Positive 9,750 (3,525)
Detectable viremia $20 cp/ml ,0.001
 no 9,098 (3,285)
 Yes 10,071 (3,909)
Detectable viremia $50 cp/ml 0.0012
 no 9,265 (3,300)
 Yes 9,959 (4,363)
Mean time from hiV infection ,0.001
 ,10 years 8,795 (2,541)
 10–20 years 9,572 (3,778)
 .20 years 10,125 (4,090)
CD4 T-cell nadir, cells/mm3 ,0.001
 #200 9,855 (3,870)
 201–499 8,944 (3,040)
 $500 8,644 (3,115)
Current CD4 T-cell count, cells/mm3 ,0.001
 #200 10,682 (4,357)
 201–499 9,656 (3,798)
 $500 9,026 (3,057)
Mean age, years 0.0003
 ,36 8,410 (2,782)
 36–50 9,388 (3,547)
 .50 9,668 (3,582)
Clinical site 0.0001
 site 1 9,168 (3,252)
 site 2 8,881 (3,600)
 site 3 10,043 (3,322)
 site 4 9,515 (2,876)
 site 5 8,728 (4,028)
Notes: *Kruskal–Wallis test. haaRT line was treated as a continuous variable.
Abbreviations: AIDS, acquired immune deficiency syndrome; cp, copies; 
haaRT, highly active antiretroviral therapy; hCV, hepatitis C virus; hiV, human 
immunodeficiency virus; IVDU, intravenous drug use; SD, standard deviation.
steps, a diagnosis of AIDS, having a viral load #50 copies/
mL and current CD4 count were added into the model, respec-
tively. For further analyses, see Supplementary material and 
Figure S1.
Finally, we also fitted the full model including all factors 
measured and collected in the database, which were found to 
be significant at univariate analyses. This was done to verify 
whether the factors identified through cross-validation had 
an independent effect on costs after controlling for all other 
variables. The results of this full regression model are shown 
in Table 3. HAART costs were independently directly cor-
related with the number of HAART lines used (the cost was 
€592 higher per each additional line of therapy used, 95% 
confidence interval 518–665, P,0.001); in contrast, they 
were inversely correlated with current CD4 T-cell count (€674 
less expensive for patients having a current CD4 count .200 
and ,500 cells/mm3 versus those having a current CD4 
count #200 cells/mm3, 95% confidence interval –1,281, –68, 
P=0.029; and €1,136 less expensive for those having a cur-
rent CD4 count of .500 cells/mm3, 95% confidence interval 
–1749, –523, P,0.001) and HCV coinfection (€527 less 
expensive than HCV-negative patients). Independent predic-
tion of higher costs was confirmed for the site of care in the 
full regression model, with marked control of expenses at site 
2 (€743 less expensive, 95% confidence interval –1139, –347, 
P,0.001) and site 5 (€1,224 less expensive, 95% confidence 
interval –1,675, –774, P,0.001).
Discussion
We evaluated the raw costs of HAART, calculated as at 
December 2012, in a multicenter Italian sample of HIV 
outpatients, to derive a comparative estimate at different sites 
of care and identify potential determinants of more costly 
HAART regimens. In our search for such determinants, we 
investigated the possible correlation between HAART costs 
and many clinical and demographic factors, including the 
burden of toxicities and comorbidities affecting the single 
patient as accounted for by a multifactorial risk score.19 
Preliminary analyses, performed for patients followed at site 
1 only, unexpectedly revealed that HAART costs were not 
correlated at all with comorbidities and HAART toxicities, as 
evaluated by such a score; in that analysis, costs were indeed 
significantly associated with other measurable factors, such 
as more advanced HAART lines, lower nadir and current 
CD4 T-cell counts, AIDS events, HCV coinfection, age, 
years from HIV diagnosis, and detectable HIV viremia. We 
therefore evaluated all these factors in this final multicenter 
sample, in order to better estimate the independent weight 
of each determinant of HAART costs.
The mean annual cost of HAART was €9,377±€3,501 
per single patient, in line with the only comparable Italian 
data, reported by Rizzardini et al, who quantified such costs 
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in the Lombardy region, finding a mean of €8,471 in 2009 
and a constant trend to annual increase.8,20
It is worth noting that each site faced with a specific 
population of patients, as shown in Table 1: site 3 took care 
of a higher percentage of previous intravenous drug users 
with a consequent higher percentage of HCV-coinfected 
patients with a lower CD4 T-cell nadir; in contrast, site 4 had 
a higher percentage of sexually infected patients with a higher 
CD4 T-cell nadir. The variability in the assisted population 
may partly determine the observed differences in HAART 
costs; such differences, however, might also reflect different 
prescribing attitudes at different sites,21 in spite of excellent 
rates of virological suppression at all sites. Detailed analysis 
of the individual regimens, not included in this retrospective 
study, may help understanding of local differences.
Analysis of the larger patient population studied here 
shows that the most powerful determinant of HAART costs 
is the line of HAART. Similar results were shown in a 
recent evaluation of HIV costs in Germany, which reported 
on increased antiretroviral experience as related to higher 
expenses.22 Given that previous treatment failures compel 
physicians to resort to newer and more expensive drugs and 
regimens, such data are easy to interpret. However, the entity 
of this association was somewhat surprising, as it emerges 
by our additional statistical analyses and appears as one of 
the most relevant findings of the present study.
In the German evaluation of HIV costs,22 Mostardt et al 
reported that a low CD4 T-cell count at evaluation was a 
strong predictor of more intensive health care utilization 
in the following year, as also shown by other authors.21,23 
Immune recovery at the time of cost calculation was indeed 
significantly related to HAART costs in our sample too, as 
patients with a good immunological response to HAART may 
be switched to less expensive regimens. Once more, future 
detailed analysis of the individual regimens (dual therapy, 
monotherapy, or others) may pinpoint specific preferences 
for simpler and less expensive strategies in such patients.
A detectable HIV viremia at the time of drug cost calcu-
lation was similarly associated with higher HAART costs. 
This is in contrast with a previous report from Rizzardini 
et al,8 indicating undetectable HIV viremia as associated 
with higher total and HAART costs for HIV care. The present 
finding, however, seems rather easy to explain, ie, virological 
failures are indeed more frequent in more advanced HAART 
lines and in patients with a longer duration of HIV infection,24 
where many drugs have already been prescribed. However, 
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viral load $50 copies/mL was associated with higher costs 
independently of the line of HAART. This might be explained 
by the fact that persistence or relapse of low level HIV 
viremia and subsequent risk of virological failure25 make 
it difficult to simplify more complex and expensive rescue 
HAART regimens, independently contributing to the costly 
management regardless of number of HAART lines used. 
However, this association of HIV viremia with HAART costs 
did not remain significant in the final multivariable model.
HAART costs were higher in patients with a lower CD4 
T-cell nadir. In our analyses, however, the correlation of costs 
with nadir CD4 T-cell count only showed a trend for signifi-
cance in the multivariable models. Immune status at HIV 
diagnosis has been repeatedly associated with higher HIV 
care costs; in a different investigational model, Krentz et al7 
showed that patients presenting with CD4 T-cell counts ,350 
cells/mm3 had 2.5 times greater total costs than less advanced 
patients, with higher costs persisting as much as 5 years 
after presentation. The CD4 T-cell nadir was also evaluated 
by Rizzardini et al.8 In their multivariable analysis, patients 
with a CD4 T-cell nadir ,200 cells/mm3 had both higher 
total costs and HAART costs.
HCV coinfection has been identified as a determinant 
of higher total costs for HIV care, as well as for HAART 
and hospital admission costs.20 Even though there was also 
a direct association between HCV coinfection and higher 
HAART costs in univariable analyses in our study, all mul-
tivariable models surprisingly showed an inverse correlation, 
ie, HCV-positive patients have lower HAART costs. In fact, 
patients with HCV coinfection had more frequently advanced 
HAART lines, and lower nadir and current CD4 T-cell 
counts, and therefore this association remains surprising.
Our evaluation has some limitations. It is a cross-sectional 
analysis that is prone to reverse causality (difficult to establish 
whether using costly drugs had an impact on patients viro-
immunological status or if, in contrast, are the level of the 
markers which are inducing different costs); moreover, the 
effect of dynamic changes in treatment usage and of surrogate 
markers of prognosis, fitted as time-dependent factors during 
the year of observation, could not be evaluated. Moreover, 
costs were calculated as an estimate from medical and phar-
macy records, and may not reflect the exact expenses for the 
Italian health system.
Conclusion
Our study provides a novel insight into the strength of dif-
ferent independent determinants of HAART costs in a large 
representative sample of Italian HIV outpatients. Higher costs 
of HAART were strongly associated with previous treatment 
failures, and lower CD4 T-cell count at the time of evaluation. 
Further analyses to clarify the contribution of the single drug/
regimen to the annual costs of HAART are warranted.
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Supplementary material
The average squared error (ASE) evolved at each step until 
final step 4 was reached and inclusion of factors terminated 
because the ten error estimates computed by cross-validation 
(CV PRESS) stopped showing a decrease using the “one-
standard-error” rule. The values for the adjusted R-square 
at the various steps were the  following: 0.146, 0.152, 0.154 
and 0.155 at step 4 which was the optimal value criterion, 
indicated with a star symbol in the Figure S1 plot. The values 
for the standard R-square were similar (not shown). Step 4 
was the chosen closing step for the chosen fit criteria of CV 
PRESS and for most of other fit criteria considered (eg, the 
adjusted R-square) or the previous step, removing current 
CD4 count (Akaike’s Information Criterion [AIC], Bayesian 
Information Criterion [BIC], see Figure S1). The ASE was 
greatly reduced when the line of highly active antiretroviral 
therapy (HAART) first entered the model. The plot of the 
improvements in ASE after the introduction of the various 
factors is key as it shows that the model including the line 
of therapy alone is a substantial improvement compared to 
the null model (with intercept only) but that adding any of 
the other factors determines only further small improve-
ments to the predictive performance. These minor changes 
of the ASE were seen on the training, validation, and test 
datasets (data not shown). Results were similar when we 
used other methods of selection, such as least absolute 
shrinkage and selection operator (LASSO) or least angle 
regression (LAR).
Fit criteria for HAART costs
AIC
AICC
BIC
Validation ASE
Effect sequence Effect sequence
Intercept 1 + HAARTl 2 + AIDS 3 + vl_20 4 + cd4_100 Intercept
Best criterion value Step selected by CV PRESS
CV PRESS
PRESS
C(p)
SBC
1 + HAARTl 2 + AIDS 3 + vl_20 4 + cd4_100
Adj R-Sq
Figure S1 Evolution of the asE at each step of the glMsElECT procedure. Factors were included in the analysis as follows: haaRT line (haaRTl), aiDs event (aiDs), 
detectable hiV viral load (vl_20), and current CD4 count (cd4_100).
Abbreviations: adj R-sq, adjusted R-squared; asE, average squared error; aiC, akaike’s infor ma tion Cri te rion; BiC, Bayesian information Criterion; haaRT, highly active 
antiretroviral therapy; lassO, least absolute shrinkage and selection operator; laR, least angle regression; aiCC, corrected akaike’s information criterion; C(p), Mallows 
statistic; sBC, schwarz Bayesian information criterion.
